probiotic

• 生菌の

関

viable cell

　

WordNet

1. a beneficial bacterium found in the intestinal tract of healthy mammals; often considered to be a plant (同)probiotic bacterium, probiotic microflora, probiotic flora

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/07/25 20:42:05」(JST)

wiki en

[Wiki en表示]

Not to be confused with Prebiotic (nutrition).

Élie Metchnikoff first suggested the possibility of colonizing the gut with beneficial flora in the early 20th century.

Probiotics are microorganisms that are believed to provide health benefits when consumed. The term probiotic is currently used to name ingested microorganisms associated with beneficial effects to humans and animals. Introduction of the concept is generally attributed to Nobel Prize recipient Élie Metchnikoff, who in 1907 suggested that "the dependence of the intestinal microbes on the food makes it possible to adopt measures to modify the flora in our bodies and to replace the harmful microbes by useful microbes". A significant expansion of the potential market for probiotics has led to higher requirements for scientific substantiation of putative beneficial effects conferred by the microorganisms. Studies on the medical benefits of probiotics have yet to reveal a cause-effect relationship, and their medical effectiveness has yet to be conclusively proven for most of the studies conducted thus far.

Commonly claimed benefits of probiotics include the decrease of potentially pathogenic gastrointestinal microorganisms, the reduction of gastrointestinal discomfort, the strengthening of the immune system, the improvement of the skin's function, the improvement of bowel regularity, the strengthening of the resistance to cedar pollen allergens, the decrease in body pathogens, the reduction of flatulence and bloating, the protection of DNA, the protection of proteins and lipids from oxidative damage, and the maintaining of individual intestinal microbiota in subjects receiving antibiotic treatment.

Scientific evidence to date has been insufficient to substantiate any antidisease claims or health benefits from consuming probiotics.

Etymology

Some literature gives it a full Greek etymology, but the term appears to be a composite of the Latin preposition pro ("for") and the Greek adjective βιωτικός (biotic), the latter deriving from the noun βίος (bios, "life").

Definition

The World Health Organization's 2001 definition of probiotics is "live micro-organisms which, when administered in adequate amounts, confer a health benefit on the host". Following this definition, a working group convened by the FAO/WHO in May 2002 issued the “Guidelines for the Evaluation of Probiotics in Food”. This first global effort was further developed in 2010, two expert groups of academic scientists and industry representatives made recommendations for the evaluation and validation of probiotic health claim. The same principles emerged from those groups as the ones expressed in the Guidelines of FAO/WHO in 2002. This definition, although widely adopted, is not acceptable to the European Food Safety Authority because it embeds a health claim which is not measurable.

A consensus definition of the term “probiotics”, based on the available information and scientific evidence, was adopted after a joint Food and Agricultural Organization of the United Nations and World Health Organization expert consultation. In October 2001, this expert consultation defined probiotics as: “live micro-organisms which, when administered in adequate amounts, confer a health benefit on the host”. The FAO/WHO consultation was also a first effort towards the assessment of probiotics efficacy and resulted in May 2002 in a document named “Guidelines for the Evaluation of Probiotics in Food”. This effort is accompanied by local governmental and supra-governmental regulatory bodies requirements to better characterize health claims substantiations.

A group of scientific experts assembled in London, UK, on October 23, 2013, to discuss the scope and appropriate use of the term probiotic. The meeting was motivated by developments in the field since 2001. The panel's conclusions were published in June, 2014.

Probiotics have to be alive when administered. One of the concerns throughout the scientific literature resides in the viability and reproducibility on a large scale of the observed results, as well as the viability and stability during use and storage, and finally the ability to survive in stomach acids and then in the intestinal ecosystem. Probiotics must have undergone controlled evaluation to document health benefits in the target host. Only products containing live organisms shown in reproducible human studies to confer a health benefit can actually claim to be a probiotic. The correct definition of health benefit, backed with solid scientific evidence, is a strong element for the proper identification and assessment of the effect of a probiotic. This aspect represents a major challenge for scientific and industrial investigations because several difficulties arise, such as variability in the site for probiotic use (oral, vaginal, intestinal) and mode of application.

The probiotic candidate must be a taxonomically defined microbe or combination of microbes (genus, species, and strain level). It is commonly admitted that most effects of probiotic are strain-specific and cannot be extended to other probiotics of the same genus or species. This calls for a precise identification of the strain, i.e. genotypic and phenotypic characterization of the tested microorganism.

Probiotics must be safe for their intended use. The 2002 FAO/WHO guidelines recommend that, though bacteria may be generally recognized as safe (GRAS), the safety of the potential probiotic should be assessed by the minimum required tests:

• Determination of antibiotic resistance patterns
• Assessment of certain metabolic activities (e.g., D-lactate production, bile salt deconjugation)
• Assessment of side effects during human studies
• Epidemiological surveillance of adverse incidents in consumers (after market)
• If the strain under evaluation belongs to a species that is a known mammalian toxin producer, it must be tested for toxin production. One possible scheme for testing toxin production has been recommended by the EU Scientific Committee on Animal Nutrition
• If the strain under evaluation belongs to a species with known hemolytic potential, determination of hemolytic activity is required

In Europe, EFSA has adopted a premarket system for safety assessment of microbial species used in food and feed productions, to set priorities for the need of risk assessment. The assessment is made for a selected group of microorganisms, which if favorable, leads to the “Qualified Presumption of Safety” status.

Finally, probiotics must be supplied in adequate numbers, which may be defined as the number able to trigger the targeted effect on the host. It depends on strain specificity, process, and matrix, as well as the targeted effect. Most of reported benefits demonstrated with the traditional probiotics have been observed after ingestion of a concentration around 10⁷ to 10⁸ probiotic cells per gram, with a serving size around 100 to 200 mg per day.

History

Probiotics have received renewed attention recently from product manufacturers, research studies, and consumers. The history of probiotics can be traced to the first use of cheese and fermented products, that were well known to the Greeks and Romans who recommended their consumption. The fermentation of dairy foods represents one of the oldest techniques for food preservation.

The original modern hypothesis of the positive role played by certain bacteria was first introduced by Russian scientist and Nobel laureate Élie Metchnikoff, who in 1907 suggested that it would be possible to modify the gut flora and to replace harmful microbes with useful microbes. Metchnikoff, at that time a professor at the Pasteur Institute in Paris, proposed the hypothesis that the aging process results from the activity of putrefactive (proteolytic) microbes producing toxic substances in the large bowel. Proteolytic bacteria such as clostridia, which are part of the normal gut flora, produce toxic substances including phenols, indols, and ammonia from the digestion of proteins. According to Metchnikoff, these compounds were responsible for what he called "intestinal autointoxication", which would cause the physical changes associated with old age.

It was at that time known that milk fermented with lactic-acid bacteria inhibits the growth of proteolytic bacteria because of the low pH produced by the fermentation of lactose. Metchnikoff had also observed that certain rural populations in Europe, for example in Bulgaria and the Russian steppes, who lived largely on milk fermented by lactic-acid bacteria were exceptionally long lived. Based on these observations, Metchnikoff proposed that consumption of fermented milk would "seed" the intestine with harmless lactic-acid bacteria and decrease the intestinal pH, and that this would suppress the growth of proteolytic bacteria. Metchnikoff himself introduced in his diet sour milk fermented with the bacteria he called "Bulgarian Bacillus" and found his health benefited. Friends in Paris soon followed his example and physicians began prescribing the sour-milk diet for their patients.

Bifidobacteria were first isolated from a breast-fed infant by Henry Tissier, who also worked at the Pasteur Institute. The isolated bacterium named Bacillus bifidus communis was later renamed to the genus Bifidobacterium. Tissier found that bifidobacteria are dominant in the gut flora of breast-fed babies and he observed clinical benefits from treating diarrhea in infants with bifidobacteria. The claimed effect was bifidobacterial displacement of proteolytic bacteria causing the disease.

During an outbreak of shigellosis in 1917, German professor Alfred Nissle isolated a strain of Escherichia coli from the feces of a soldier who was not affected by the disease. Methods of treating infectious diseases were needed at that time when antibiotics were not yet available, and Nissle used the E. coli Nissle 1917 strain in acute gastrointestinal infectious salmonellosis and shigellosis.

In 1920, Rettger and Cheplin reported that Metchnikoff's "Bulgarian Bacillus", later called Lactobacillus delbrueckii subsp. bulgaricus, could not live in the human intestine. They conducted experiments involving rats and humans volunteers, by feeding them with Lactobacilus acidophilus. They observed changes in composition of fecal microbiota, which they described as “transformation of the intestinal flora”. Rettger further explored the possibilities of L. acidophilus and reasoned that bacteria originating from the gut were more likely to produce the desired effect in this environment. In 1935, certain strains of L. acidophilus were found to be very active when implanted in the human digestive tract. Trials were carried out using this organism, and encouraging results were obtained, especially in the relief of chronic constipation.

According to Hamilton-Miller et al., in a letter in which they call for the oldest known citation of the word, the term "probiotics" was first introduced in 1953 by Werner Kollath to describe organic and inorganic food supplements applied to restore health to patients suffering from malnutrition. Contrasting antibiotics, probiotics were defined as microbially derived factors that stimulate the growth of other microorganisms. In 1989, Roy Fuller suggested a definition of probiotics that has been widely used: "A live microbial feed supplement which beneficially affects the host animal by improving its intestinal microbial balance". Fuller's definition emphasizes the requirement of viability for probiotics and introduces the aspect of a beneficial effect on the host.

The term "probiotic" originally referred to microorganisms that have effects on other microorganisms. The conception of probiotics involved the notion that substances secreted by one microorganism stimulated the growth of another microorganism. The term was used again to describe tissue extracts which stimulated microbial growth. The term probiotics was taken up by Parker, who defined the concept as, “organisms and substances that have a beneficial effect on the host animal by contributing to its intestinal microbial balance”. Later, the definition was greatly improved by Fuller, whose explanation was very close to the definition used today. Fuller 89 described probiotics as a "live microbial feed supplement which beneficially affects the host animal by improving its intestinal microbial balance". He stressed two important facts of probiotics: the viable nature of probiotics and the capacity to help with intestinal balance.

In the following decades, intestinal lactic acid bacterial species with alleged health beneficial properties have been introduced as probiotics, including Lactobacillus rhamnosus, Lactobacillus casei, and Lactobacillus johnsonii.

Research

Probiotics are under considerable research, as the concept holds promise for human health and well-being, and corresponding commercial opportunities. Protection of consumers requires health claims to be confirmed with sufficient scientific evidence. Overall scientific demonstration of probiotic effects requires defining a healthy microbiota and interactions between microbiota and host, and the difficulty to characterize probiotic effectiveness in health and disease. Recent developments of high-throughput sequencing technology and the consequent progresses of metagenomics represent a new approach for the future of probiotics research.

Studies are examining whether probiotics affect mechanisms of intestinal inflammation, diarrhea, or urogenital infections Through 2012, however, in all cases proposed as health claims to the European Food Safety Authority, the scientific evidence remains insufficient to prove a cause and effect relationship between consumption of probiotic products and any health benefit.

Research into the potential health effects of supplemental probiotics has included the molecular biology and genomics of Lactobacillus in immune function, cancer, and antibiotic-associated diarrhea, travellers' diarrhea, pediatric diarrhea, inflammatory bowel disease, and irritable bowel syndrome. Testing of a probiotic applies to a specific strain under study. The scientific community cautions against extrapolating an effect from a tested strain to an untested strain.

Although research does suggests that the relationship between gut flora and humans is a mutualistic relationship, very little evidence supports claims that probiotic dietary supplements have any health benefits. Improved health through gut flora modulation appears to be directly related to long-term dietary changes.

In a 2009 blog post, one expert reasoned that preliminary clinical results exist for some applications, such as treating diarrhea, but wider health benefits claimed by probiotic proponents lack plausibility since the body's "ecosystem" is sufficiently complex that adding a few bacteria is unlikely to have the claimed effect. Accordingly, he reasoned, "the alleged health benefits of probiotics are often an example of spin". Since then, there has been an increase in the body of scientific evidence supporting the use of specific probiotics to improve health (See table on Probiotic strains section). Although the body's complex microbial community is incompletely understood at present, there is strong scientific consensus on the benefits of using of probiotics to address certain medical states or conditions.

Claims that some lactobacilli may contribute to weight gain in some humans remain controversial.

Allergies

Probiotics are ineffective in preventing allergies in children, with the possible exception of eczema.

Diarrhea

Some probiotics are suggested as a possible treatment for various forms of gastroenteritis, and a Cochrane Collaboration meta-analysis on the use of probiotics to treat acute infectious diarrhea based on a comprehensive review of medical literature through 2010 (35 relevant studies, >4500 participants) reported that use of any of the various tested probiotic formulations appeared to reduce the duration of diarrhea by a mean of 25 hours (vs. control groups, 95% confidence interval, 16–34 hours), also noting, however, that "the differences between the studies may be related to other unmeasured and unexplored environmental and host factors" and that further research was needed to confirm reported benefits.

Antibiotic-associated diarrhea

Some of the best evidence in support of probiotic health benefits is in the treatment of antibiotic-associated diarrhea (AAD). Antibiotics are a common treatment for children, and 20% of antibiotic-treated children develop diarrhea. AAD results from an imbalance in the colonic microbiota caused by antibiotic therapy. Microbiota alteration changes carbohydrate metabolism, with decreased short-chain fatty acid absorption and osmotic diarrhea as a result. The preventive role of some probiotics has been correctly assessed in randomized, controlled clinical trials. A review assessing the work of 16 different studies representing the evaluation of more than 3,400 patients concluded that the evidence gathered suggested a protective effect of some probiotics in this condition. In adults, some probiotics showed a beneficial role in reducing the occurrence of AAD. Another consequence of antibiotic therapy leading to diarrhea is the overgrowth of potentially pathogenic organisms such as Clostridium difficile.

Probiotic treatment might reduce the incidence and severity of AAD as indicated in several meta-analyses. For example, treatment with probiotic formulations including L. rhamnosus may reduce the risk of AAD, improve stool consistency during antibiotic therapy, and enhance the immune response after vaccination. However, further documentation of these findings through randomized, double-blind, placebo-controlled trials is required to confirm specific effects and obtain regulatory approval, which currently does not exist.

The potential efficacy of probiotic AAD prevention is dependent on the probiotic strain(s) used and on the dosage. A Cochrane Collaboration systematic review, in which 16 randomized clinical trials (n=3432 participants) were analyzed, concluded that treatments with less than 5000 million CFUs/day did not show a significant decrease of AAD. However, patients treated with ≥5000 million CFUs/day (including L. rhamnosus and Saccharomyces boulardii) had 60% lower relative risk (95%CI: 44–71%) of experiencing AAD than untreated patients.

Lactose intolerance

Ingestion of certain active strains may help lactose-intolerant individuals tolerate more lactose than they would otherwise have tolerated.

Cholesterol

Preliminary human and animal studies have demonstrated the efficacy of some strains of lactic acid bacteria (LAB) for reducing serum cholesterol levels, presumably by breaking down bile in the gut, thus inhibiting its reabsorption (where it enters the blood as cholesterol).

A meta-analysis that included five double-blind trials examining the short-term (2–8 weeks) effects of a yogurt with probiotic strains on serum cholesterol levels found a minor change of 8.5 mg/dL (0.22 mmol/L) (4% decrease) in total cholesterol concentration, and a decrease of 7.7 mg/dL (0.2 mmol/L) (5% decrease) in serum LDL concentration.

A slightly longer study evaluating the effect of a yogurt with probiotic strains on 29 subjects over six months found no statistically significant differences in total serum cholesterol or LDL values. However, the study did note a significant increase in serum HDL from, 50 to 62 mg/dL (1.28 to 1.6 mmol/L) following treatment. This corresponds to a possible improvement of LDL/HDL ratio.

Studies specifically on hyperlipidemic subjects are still needed.

Blood pressure

The consumption of probiotics may effect a modest benefit in helping to control high blood pressure.

Immune function and infections

Some strains of LAB may affect pathogens by means of competitive inhibition (i.e., by competing for growth) and some evidence suggests they may improve immune function by increasing the number of IgA-producing plasma cells and increasing or improving phagocytosis, as well as increasing the proportion of T lymphocytes and natural killer cells. Clinical trials have demonstrated that probiotics may decrease the incidence of respiratory-tract infections and dental caries in children. LAB products might aid in the treatment of acute diarrhea, and possibly affect rotavirus infections in children and travelers' diarrhea in adults, but no products are approved for such indications.

Helicobacter pylori

Some strains of LAB may affect Helicobacter pylori infections (which may cause peptic ulcers) in adults when used in combination with standard medical treatments, but no standard in medical practice or regulatory approval exists for such treatment.

Inflammation

Some strains of LAB may modulate inflammatory and hypersensitivity responses, an observation thought to be at least in part due to the regulation of cytokine function. Clinical studies suggest they can prevent reoccurrences of inflammatory bowel disease in adults, as well as improve milk allergies. How probiotics may influence the immune system remains unclear, but a potential mechanism under research concerns the response of T lymphocytes to proinflammatory stimuli.

Irritable bowel syndrome and colitis

Probiotics may help people with irritable bowel syndrome, although uncertainty remains around which type of probiotic works best, and around the size of the effect.

No good evidence indicates taking probiotics helps maintain remission from ulcerative colitis.

Necrotizing enterocolitis

Several clinical studies provide evidence for the potential of probiotics to lower the risk of necrotizing enterocolitis (NEC) and mortality in premature infants. One meta-analysis indicated that probiotics reduce all-cause mortality and risk of having NEC by more than 50% compared with controls.

Vitamin production

Probiotic treatment has been studied as a means of addressing maladies associated with vitamin deficiency, e.g., of vitamin K, folic acid, and vitamin B12.

Eczema

Probiotics are commonly given to breast-feeding mothers and their young children to prevent eczema, but some doubt exists over the strength of evidence supporting this practice.

Bacterial Vaginosis

Probiotic treatment of bacterial vaginosis is the application or ingestion of bacterial species found in the healthy vagina to cure the infection of bacteria causing bacterial vaginosis. This treatment is based on the observation that 70% of healthy females have a group of bacteria in the genus Lactobacillus that dominate the population of organisms in the vagina. Currently, the success of such treatment has been mixed since the use of probiotics to restore healthy populations of Lactobacillus has not been standardized. Often, standard antibiotic treatment is used at the same time that probiotics are being tested. In addition, some groups of women respond to treatment based upon ethnicity, age, number of sexual partners, pregnancy, and the pathogens causing bacterial vaginosis. In 2013, researchers found that administration of hydrogen peroxide producing strains, such as L. acidophilus and L. rhamnosus, were able to normalize vaginal pH and rebalance vaginal flora, preventing and alleviating bacterial vaginosis.

Side effects

In some situations, such as where the person consuming probiotics is critically ill, probiotics could be harmful. In a therapeutic clinical trial conducted by the Dutch Pancreatitis Study Group, the consumption of a mixture of six probiotic bacteria increased the death rate of patients with predicted severe acute pancreatitis.

In a clinical trial aimed at showing the effectiveness of probiotics in reducing childhood allergies, researchers gave 178 children either a probiotic or a placebo for the first six months of their lives. Those given the probiotic were more likely to develop a sensitivity to allergens.

Some hospitals have reported treating Lactobacillus septicaemia, which is a potentially fatal disease caused by the consumption of probiotics by people with lowered immune systems or who are already very ill.

Probiotics taken orally can be destroyed by the acidic conditions of the stomach. A number of microencapsulation techniques are being developed to address this problem.

One 2009 paper cited a 2007 study in chickens as a support for causally linked probiotic products such as yogurts with obesity trends. However, this is contested as the link to obesity, and other health-related issues with yogurt may link to its dairy and calorie attributes.

Some experts are skeptical on the efficacy of many strains and believe not all subjects will benefit from the use of probiotics.

Strains

Live probiotic cultures are available in fermented dairy products and probiotic fortified foods. However, tablets, capsules, powders, and sachets containing the bacteria in freeze-dried form are also available.

Only preliminary evidence exists for most probiotic health claims. Even for the most studied strains, few have been sufficiently developed in basic and clinical research to warrant approval for health claim status to a regulatory agency such as the Food and Drug Administration or European Food Safety Authority, and to date, no claims have been approved by those two agencies.

For the variety of strains with imputed potential health benefits, see the research section above. Some additional forms of lactic acid bacteria include Lactobacillus bulgaricus, Streptococcus thermophilus, and "Lactobacillus bifidus".

Some fermented products are reported to contain similar lactic acid bacteria, including pickled vegetables, fermented bean paste such as tempeh, miso, and doenjang, kefir, buttermilk or karnemelk, kimchi pao cai, sauerkraut, soy sauce, and zha cai.

Commercial probiotics

Labeling ambiguities

The National Yogurt Association gives a Live & Active Cultures seal to yogurt products which contain 10⁸ CFU/mL cultures per gram (at the time of manufacture). In 2002, the US FDA and World Health Organization recommended that “the minimum viable numbers of each probiotic strain at the end of the shelf-life” be reported on labeling, but most companies that give a number report the viable cell count at the date of manufacture, a number probably much higher than existing at the moment of consumption. Because of variability in storage conditions and time before eating, it is difficult to tell exactly how much active culture remains at the time of consumption. Due to these ambiguities, in 2012, the European Commission placed a ban on putting the word “probiotic” on the packaging of products because such labeling misleads consumers to believe a health benefit is provided by the product when no scientific proof exists to demonstrate that health effect.

History and modern products

The first commercially sold dairy-based probiotic was Yakult, a fermented milk with added Lactobacillus casei Shirota, in 1935. Since then, many more probiotic foods have come on the market, mostly in the form of dairy products. Recently, nondairy and unfermented probiotics have been produced, including breakfast cereal and snack bars, whereas other probiotic products include kefir, yogurt, kombucha, kimchi, sauerkraut, and other fermented foods and beverages.

Global consumption

Sales of probiotic products have a rising trend from 2010 to 2014, increasing globally by 35% from US$23.1 billion to $31.3 billion. Some regions have increased their use by even more than the average, including Eastern Europe (67%), Asia Pacific (67%), and Latin America (47%), comprising nearly half of probiotics sold globally in 2014. By geographic region, the leading consumers of probiotics in 2014 were Western Europe ($8.3 billion), Asia Pacific ($7 billion), Japan ($5.4 billion), Latin America ($4.8 billion), North America ($3.5 billion), and Eastern Europe ($2.3 billion).

EFSA scientific review of probiotics

The European Food Safety Authority has so far rejected 260 claims on probiotics in Europe due to insufficient research and thus inconclusive proof. The review did not refute the potential for effectiveness, but rather that a cause-effect relationship had not been sufficiently established in studies to date. The claims rejected include:

• Lactobacillus paracasei LMG P 22043 decreases potentially pathogenic gastrointestinal microorganisms or reduce gastrointestinal discomfort.
• Lactobacillus johnsonii BFE 6128 - immunity and skin claims (all too general for consideration)
• Lactobacillus fermentum ME-3 decreases potentially pathogenic gastrointestinal microorganisms.
• Lactobacillus plantarum BFE 1685 - immunity claim (deemed too general)
• Bifidobacterium longum BB536 improves bowel regularity, resists cedar pollen allergens, and decreases pathogens.
• Lactobacillus plantarum 299v reduces flatulence and bloating and protects DNA, proteins, and lipids from oxidative damage.
• Lactobacillus rhamnosus LB21 NCIMB 40564 helps maintain individual intestinal microbiota in subjects receiving antibiotic treatment.

Multiple probiotics

Preliminary research is evaluating the potential physiological effects of multiple probiotic strains, as opposed to a single strain. As the human gut may contain several hundred microbial species, one theory indicates that this diverse environment may benefit from consuming multiple probiotic strains, an effect that remains scientifically unconfirmed.

See also

• Fecal bacteriotherapy
• Functional food
• Microbial food cultures
• Prebiotic (nutrition)
• Synbiotics
• Probiotics in pediatrics

References

Further reading

• Francisco Guarner, Gabriela Perdigon, Ge ́rard Corthier, Seppo Salminen, Berthold Koletzko & Lorenzo Morelli, 2005, "Should yoghurt cultures be considered probiotic?," British Journal of Nutrition 93:783–786, DOI 10.1079/BJN20051428, see [4], accessed 11 June 2015.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 消化器疾患に対するプロバイオティクス probiotics for gastrointestinal diseases
• 2. クロストリジウム・ディフィシルとプロバイオティクス clostridium difficile and probiotics
• 3. アレルギー疾患の治療のためのプレバイオティクスおよびプロバイオティクス prebiotics and probiotics for treatment of allergic disease
• 4. アレルギー性疾患の予防のためのプレバイオティクスおよびプロバイオティクス prebiotics and probiotics for prevention of allergic disease
• 5. 資源の豊富な国の小児における慢性下痢症の診断へのアプローチ approach to the diagnosis of chronic diarrhea in children in resource rich countries

English Journal

• Metabarcoding of the kombucha microbial community grown in different microenvironments.

• Reva ON1, Zaets IE, Ovcharenko LP, Kukharenko OE, Shpylova SP, Podolich OV, de Vera JP, Kozyrovska NO.
• AMB Express.AMB Express.2015 Dec;5(1):124. doi: 10.1186/s13568-015-0124-5. Epub 2015 Jun 11.
• Introducing of the DNA metabarcoding analysis of probiotic microbial communities allowed getting insight into their functioning and establishing a better control on safety and efficacy of the probiotic communities. In this work the kombucha poly-microbial probiotic community was analysed to study it
• PMID 26061774

• Study of the effect of different fermenting microorganisms on the Se, Cu, Cr, and Mn contents in fermented goat and cow milks.

• Quintana AV1, Olalla-Herrera M1, Ruiz-López MD1, Moreno-Montoro M1, Navarro-Alarcón M2.
• Food chemistry.Food Chem.2015 Dec 1;188:234-9. doi: 10.1016/j.foodchem.2015.05.008. Epub 2015 May 2.
• The aim of this study was to determine the Se, Cu, Cr, and Mn concentrations of different types of goat- and cow-milk fermented products and evaluate the influence of fermenting bacteria (classical fermenting starters and a probiotic strain) on these concentrations. Atomic absorption spectrometry wi
• PMID 26041187

• Does Lactobacillus plantarum or ultrafiltration process improve Ca, Mg, Zn and P bioavailability from fermented goats' milk?

• Bergillos-Meca T1, Cabrera-Vique C2, Artacho R2, Moreno-Montoro M2, Navarro-Alarcón M2, Olalla M2, Giménez R2, Seiquer I3, Ruiz-López MD2.
• Food chemistry.Food Chem.2015 Nov 15;187:314-21. doi: 10.1016/j.foodchem.2015.04.051. Epub 2015 Apr 21.
• Ca, Mg, Zn and P bioavailability from two experimental ultrafiltered fermented goats' milks (one of them with the probiotic Lactobacillus plantarum and another one without it), and fermented goats' milk samples available in the market were evaluated. Solubility, dialysability and a model combining s
• PMID 25977032

Japanese Journal

• プロバイオティクス菌株の簡易かつ迅速な選定方法の開発 (特集 アクアフォトミクスによる生体計測・診断および食品の品質評価技術)

• 小柴 春樹,ALEKSANDAR Slavchev,Kovacs Zoltan [他]
• 農業食料工学会誌 = Journal of the Japanese Society of Agricultural Machinery and Food Engineers 77(3), 146-150, 2015-05
• NAID 40020473600

• Subacute ruminal acidosis (SARA) challenge, ruminal condition and cellular immunity in cattle

• Sato Shigeru
• Japanese Journal of Veterinary Research 63(1), S25-S36, 2015-02
• … SARA calves given a 5-day repeated administration of a bacteria-based probiotic had stable ruminal pH levels (6.6-6.8). …
• NAID 120005540301

• 発酵乳製品継続摂取による高齢者福祉施設入居者の排便状況の改善

• 関田 頼子,時田 佳代子,時田 純,西山 八重子,生田目 圭子,内田 加代子,久代 明,饗場 直美
• 日本栄養士会雑誌 58(6), 440-445, 2015
• 特別養護老人ホーム潤生園では、2009年9月より入居者のQOLの向上を目的に、発酵乳製品を毎日1個摂取している（乳酸菌飲料週4回、ヨーグルト週3回）。当園では摂取開始以前より入居者の健康状態や排便状況をデータベース化しており、摂取前後のデータを比較することで、発酵乳製品の継続摂取が入居者の排便状況や健康状態に、どのような影響を及ぼすかを検証した。月平均の排便回数は摂取後、有意に増加していた（月平均 …
• NAID 130005072306

Related Links

• 乳酸菌

乳酸菌は最も重要な栄養素です。乳酸菌サプリメント、プロバイオティクス、乳酸菌ドリンク、色んなプロバイオティクスがありますが、自閉症の胃腸消化改善からカンジダ菌の保護、子供乳酸菌、ベビー乳酸菌、シニア乳酸菌、女性 ...

• What Are Probiotics? Benefits, Supplements, Foods, & More

An overview of probiotics – their benefits and how they work, supplements and foods with probiotics, the best probiotics for different conditions, and possible side effects. ... Crohn's disease, an inflammatory bowel disease affecting ...

Related Pictures

---

★リンクテーブル★

リンク元	「viable cell」「生菌」

「viable cell」

　　[★]

• 生細胞、生存細胞、生菌

関

living cell、probiotic

「生菌」

　　[★]

英

viable cell、probiotic

関

生細胞、生存細胞